Author:
Mifsud Edin J.,Tilmanis Danielle,Oh Ding Yuan,Ming-Kay Tai Celeste,Rossignol Jean-Francois,Hurt Aeron C.
Funder
Australian Government Department of Health
Reference43 articles.
1. The unintended mitochondrial uncoupling effects of the FDA-approved anti-helminth drug nitazoxanide mitigates experimental parkinsonism in mice;Amireddy;J. Biol. Chem.,2017
2. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial;Beigel;Lancet Infect. Dis.,2017
3. Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro;Belardo;Antimicrob. Agents Chemother.,2015
4. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit;Byrn;Antimicrob. Agents Chemother.,2015
5. Synergy evaluation of anti-Herpes Simplex Virus type 1 and 2 compounds acting on different steps of virus life cycle;Criscuolo;Antivir. Res.,2018
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献